{"product_id":"tesamorelin-10mg","title":"Tesamorelin 10mg","description":"\u003ch1 class=\"p1\"\u003eWhat is Tesamorelin?\u003c\/h1\u003e\n\u003cp\u003eTesamorelin is a synthetic peptide analog of GHRH (Growth Hormone-Releasing Hormone), created to stimulate endogenous growth hormone release by interacting with GHRH receptors in the pituitary gland. Unlike direct growth hormone administration, Tesamorelin acts by activating natural pituitary GH secretion.\u003c\/p\u003e\n\n\u003cp\u003eIn scientific literature, Tesamorelin has been primarily discussed in relation to the regulation of the GH\/IGF-1 axis, visceral adipose tissue, lipid metabolism, and metabolic risk. Its best-documented clinical data are in HIV-associated lipodystrophy, where it has been studied for its effect on abdominal visceral adipose tissue.\u003c\/p\u003e\n\n\u003cp\u003eOne of the most frequently discussed aspects of Tesamorelin is its ability to stimulate pulsatile growth hormone release, which secondarily leads to an increase in IGF-1. In research and clinical models, this has been associated with changes in body composition, lipolysis, fat distribution, and certain indicators of metabolic function.\u003c\/p\u003e\n\n\u003ch2 class=\"p1\"\u003eObservations with Tesamorelin\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGH\/IGF-1 axis\u003c\/strong\u003e – discussed in relation to stimulating endogenous growth hormone release and increasing IGF-1.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eVisceral adipose tissue\u003c\/strong\u003e – in clinical studies, an effect on the reduction of abdominal visceral fat has been described in specific study populations.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eMetabolic processes\u003c\/strong\u003e – studied in relation to lipid profile, energy balance, and fat metabolism regulation.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eHepatic steatosis\u003c\/strong\u003e – in some scientific literature, Tesamorelin has been studied in HIV-associated fatty liver disease and changes in liver fat.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eBody composition\u003c\/strong\u003e – discussed in relation to fat tissue distribution, waist circumference, and changes in the visceral fat compartment.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eCellular and hormonal regulation\u003c\/strong\u003e – studied as a model for the relationship between GHRH signaling, GH secretion, IGF-1, and metabolic adaptation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eScientific Data\u003c\/h2\u003e\n\u003cp\u003eIn clinical studies, Tesamorelin has been described as a synthetic GHRH analog that stimulates pituitary growth hormone secretion. The increase in GH leads to a secondary increase in IGF-1, which is used as an important marker for the activity of the GH axis.\u003c\/p\u003e\n\n\u003cp\u003eThe most strongly documented data are related to HIV-associated lipodystrophy. In these models, Tesamorelin has been studied for its ability to reduce visceral adipose tissue without acting as a direct replacement for growth hormone. Some studies have described changes in waist circumference, body composition, and certain lipid parameters.\u003c\/p\u003e\n\n\u003cp\u003eAdditional publications discuss Tesamorelin in HIV-associated non-alcoholic fatty liver disease. In this context, the peptide has been studied in relation to liver fat, metabolic regulation, inflammatory processes, and potential influence on fibrotic progression.\u003c\/p\u003e\n\n\u003ch2\u003ePotential effects discussed in scientific literature\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eStimulation of endogenous growth hormone secretion\u003c\/li\u003e\n\u003cli\u003eIncrease in IGF-1 as a marker for GH axis activity\u003c\/li\u003e\n\u003cli\u003eReduction of visceral adipose tissue in certain study populations\u003c\/li\u003e\n\u003cli\u003eInfluence on body composition and abdominal fat distribution\u003c\/li\u003e\n\u003cli\u003eChanges in lipid profile and metabolic indicators\u003c\/li\u003e\n\u003cli\u003eResearch interest in HIV-associated lipodystrophy\u003c\/li\u003e\n\u003cli\u003ePotential link with hepatic steatosis and fatty infiltration\u003c\/li\u003e\n\u003cli\u003eInvolvement in the regulation of energy balance and lipolysis\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp\u003eIn scientific and clinical literature, Tesamorelin is described with subcutaneous administration within controlled protocols. The most commonly discussed clinical regimens involve once-daily administration, and this data is provided for informational purposes only and does not constitute a recommendation for use.\u003c\/p\u003e\n\n\u003cp\u003eExample concentrations for 5 mg \/ 2 ml solution:\u003c\/p\u003e\n\u003cp\u003e0.2 ml = 0.5 mg\u003c\/p\u003e\n\u003cp\u003e0.4 ml = 1 mg\u003c\/p\u003e\n\u003cp\u003e0.6 ml = 1.5 mg\u003c\/p\u003e\n\u003cp\u003e0.8 ml = 2 mg\u003c\/p\u003e\n\n\u003cp\u003eExample concentrations for 10 mg \/ 2 ml solution:\u003c\/p\u003e\n\u003cp\u003e0.1 ml = 0.5 mg\u003c\/p\u003e\n\u003cp\u003e0.2 ml = 1 mg\u003c\/p\u003e\n\u003cp\u003e0.3 ml = 1.5 mg\u003c\/p\u003e\n\u003cp\u003e0.4 ml = 2 mg\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eIn clinical and research data, Tesamorelin is generally described as well-tolerated, but reactions related to both the injection site and the activation of the GH\/IGF-1 axis may be observed. Reported reactions include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eredness, itching, or discomfort at the injection site\u003c\/li\u003e\n\u003cli\u003emuscle or joint pain\u003c\/li\u003e\n\u003cli\u003efluid retention\u003c\/li\u003e\n\u003cli\u003eheadache\u003c\/li\u003e\n\u003cli\u003enumbness or tingling sensation in the extremities\u003c\/li\u003e\n\u003cli\u003eincrease in IGF-1 in sensitive individuals\u003c\/li\u003e\n\u003cli\u003echanges in glucose metabolism in certain at-risk groups\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDue to its influence on the GH\/IGF-1 axis, in a clinical context, parameters such as IGF-1, glucose, HbA1c, and overall metabolic status are monitored. The data should not be automatically applied to healthy individuals or other populations outside of the specific study groups.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThe information is summarized based on available scientific publications and is for educational purposes only. It should not be used for diagnosis, treatment, or prevention of diseases.\u003c\/em\u003e\u003c\/p\u003e","brand":"Store","offers":[{"title":"10mg","offer_id":53618489131351,"sku":null,"price":73.75,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/Tesamorelin_8c44169b-0e78-4605-ba6e-62b1f340ea5c.png?v=1779544834","url":"https:\/\/purepeptide.eu\/products\/tesamorelin-10mg","provider":"PurePeptide","version":"1.0","type":"link"}